Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3086-3091

  Miller, Benjamin ^a   Hershberger, Ellie ^a   Benziger, David ^a   Trinh, MyMy ^b   Friedland, Ian ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b Pharsight A Certara Company   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE; TAZOBACTAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; BLOOD CLOTTING; BODY ACHE; CONSTIPATION; CONTROLLED STUDY; COOMBS TEST; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEADACHE; HEMATOLOGY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PAIN; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VITAL SIGN; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; YOUNG ADULT;

EID: 84861121314     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06349-11     Document Type: Article

References (9)

1. Boucher HW, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
2. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12. (Pubitemid 28068148)
3. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. 2010. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single-and multiple-dose intravenous infusions. Antimicrob. Agents Chemother. 54:3427-3431.
4. Halstenson CE, et al. 1994. Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin-tazobactam in subjects with renal impairment. J. Clin. Pharmacol. 34:1208-1217.
5. Maragakis LL, Perencevich EN, Cosgrove SE. 2008. Clinical and economic burden of antimicrobial resistance. Expert Rev. Anti-Infect. Ther. 6:751-763.
6. Moya B, et al. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54:1213-1217.
7. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob. Agents Chemother. 55:2390-2394.
8. Titelman E, Karlsson IM, Ge Y, Giske CG. 2011. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 70:137-141.
9. Wise R, Logan M, Cooper M, Andrews JM. 1991. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob. Agents Chemother. 35:1081-1084.